Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With
calreticulin
cancer immune therapy
cancer vaccines
myeloproliferative neoplasms
neo-antigen
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
12
2020
accepted:
18
01
2021
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
The calreticulin ( The safety and efficacy of vaccination with the peptide CALRLong36 derived from the Patients had a median age of 59.5 years and a median disease duration of 6.5 years. All patients received the intended 15 vaccines, and the vaccines were deemed safe and tolerable as only two grade three AE were detected, and none of these were considered to be related to the vaccine. A decline in platelet counts relative to the platelets counts at baseline was detected during the first 100 days, however this did not translate into neither a clinical nor a molecular response in any of the patients. Immunomonitoring revealed that four of 10 patients had an Therapeutic cancer vaccination with peptide vaccines derived from mutant
Sections du résumé
BACKGROUND
BACKGROUND
The calreticulin (
METHODS
METHODS
The safety and efficacy of vaccination with the peptide CALRLong36 derived from the
RESULTS
RESULTS
Patients had a median age of 59.5 years and a median disease duration of 6.5 years. All patients received the intended 15 vaccines, and the vaccines were deemed safe and tolerable as only two grade three AE were detected, and none of these were considered to be related to the vaccine. A decline in platelet counts relative to the platelets counts at baseline was detected during the first 100 days, however this did not translate into neither a clinical nor a molecular response in any of the patients. Immunomonitoring revealed that four of 10 patients had an
CONCLUSION
CONCLUSIONS
Therapeutic cancer vaccination with peptide vaccines derived from mutant
Identifiants
pubmed: 33718228
doi: 10.3389/fonc.2021.637420
pmc: PMC7952976
doi:
Banques de données
ClinicalTrials.gov
['NCT03566446']
Types de publication
Journal Article
Langues
eng
Pagination
637420Informations de copyright
Copyright © 2021 Handlos Grauslund, Holmström, Jørgensen, Klausen, Weis-Banke, El Fassi, Schöllkopf, Clausen, Gjerdrum, Breinholt, Kjeldsen, Hansen, Koschmieder, Chatain, Novotny, Petersen, Kjær, Skov, Met, Svane, Hasselbalch and Andersen.
Déclaration de conflit d'intérêts
MOH, HH, and MA have filed a patent regarding the CALR exon 9 mutations as a target for cancer immune therapy. The patent has been transferred to University Hospital Zealand, Zealand Region and Copenhagen University Hospital at Herlev, Capital Region according to Danish Law concerning inventions made at public research institutions. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2016 Mar 10;127(10):1307-16
pubmed: 26817954
Hum Immunol. 1992 Apr;33(4):266-74
pubmed: 1639630
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
Cell Mol Immunol. 2012 Jul;9(4):302-9
pubmed: 22705915
J Clin Invest. 2015 Sep;125(9):3401-12
pubmed: 26214521
Clin Cancer Res. 2014 Sep 15;20(18):4758-67
pubmed: 25037736
Blood. 2014 Oct 16;124(16):2507-13; quiz 2615
pubmed: 25037629
Blood Cancer J. 2019 Jan 17;9(2):8
pubmed: 30655510
Int J Cancer. 2011 Mar 1;128(5):1120-8
pubmed: 20473937
Leukemia. 2017 Mar;31(3):697-704
pubmed: 27654852
Oncoimmunology. 2020 Jun 1;9(1):1771142
pubmed: 32923127
Blood. 2013 Aug 22;122(8):1395-8
pubmed: 23838352
J Hematol Oncol. 2016 May 13;9(1):45
pubmed: 27177927
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
Cancer Immunol Immunother. 2010 Oct;59(10):1489-501
pubmed: 20549207
N Engl J Med. 2009 Nov 5;361(19):1838-47
pubmed: 19890126
Nature. 1999 Oct 14;401(6754):708-12
pubmed: 10537110
Leuk Res. 2019 Apr;79:52-59
pubmed: 30851544
J Immunother. 1999 Mar;22(2):155-65
pubmed: 10093040
Oncoimmunology. 2018 Feb 27;7(6):e1433521
pubmed: 29872567
N Engl J Med. 2006 Dec 7;355(23):2452-66
pubmed: 17151367
Leukemia. 2016 Apr;30(4):776-81
pubmed: 26601783
Haematologica. 2010 Jul;95(7):1216-20
pubmed: 20053870
Nature. 2017 Nov 23;551(7681):512-516
pubmed: 29132146
Blood. 2011 Aug 25;118(8):2170-3
pubmed: 21708889
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Blood. 2013 Aug 8;122(6):1087-8
pubmed: 23929838
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
Cancer Res. 2015 Jun 1;75(11):2187-99
pubmed: 25832652
Leukemia. 2013 Apr;27(4):803-12
pubmed: 23238589
Leuk Lymphoma. 2018 Apr;59(4):973-977
pubmed: 28792253
Leuk Lymphoma. 2016 Feb;57(2):348-354
pubmed: 25956046
Blood. 2003 Dec 1;102(12):3912-8
pubmed: 12920019
Cancer Res. 1995 Jul 15;55(14):2984-7
pubmed: 7606715
Blood. 2008 Oct 15;112(8):3065-72
pubmed: 18650451
Mol Cell. 2020 Feb 20;77(4):748-760.e9
pubmed: 31785928
Blood. 2013 Aug 15;122(7):1192-202
pubmed: 23770777
Blood. 2014 Aug 14;124(7):1062-9
pubmed: 24986690
Cancer Res. 2013 Mar 15;73(6):1764-76
pubmed: 23328583
Cancer Immunol Immunother. 1995 Mar;40(3):165-72
pubmed: 7728775
Semin Immunopathol. 2019 Jan;41(1):87-95
pubmed: 29968045
Blood. 2006 Nov 15;108(10):3472-6
pubmed: 16868251
PLoS One. 2012;7(4):e34568
pubmed: 22539948
Leukemia. 2016 Dec;30(12):2413-2416
pubmed: 27560107
Cancer Immunol Immunother. 2020 Feb;69(2):315-324
pubmed: 31915854
J Clin Oncol. 2005 Aug 20;23(24):5779-87
pubmed: 16110035
Am J Hematol. 1999 May;61(1):10-5
pubmed: 10331505
Blood. 2012 Aug 9;120(6):1282-9
pubmed: 22592607
Cancer Discov. 2016 Apr;6(4):368-81
pubmed: 26951227
Br J Haematol. 2012 Oct;159(2):172-81
pubmed: 22909192
Br J Haematol. 2015 Jun;169(6):824-33
pubmed: 25824483
Leukemia. 2018 Feb;32(2):429-437
pubmed: 28676668
Blood. 2019 Aug 1;134(5):469-479
pubmed: 31217187
Blood. 2013 Jun 6;121(23):4778-81
pubmed: 23591792
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
Curr Hematol Malig Rep. 2014 Dec;9(4):331-9
pubmed: 25139710
Nat Rev Cancer. 2012 Mar 01;12(4):307-13
pubmed: 22378190
Leukemia. 2016 Aug;30(8):1759-63
pubmed: 26883579
Oncoimmunology. 2017 Nov 1;7(2):e1390641
pubmed: 29308318
Cancer Immunol Immunother. 2008 Sep;57(9):1413-20
pubmed: 18297281
Cancer Res. 2012 Dec 1;72(23):6102-10
pubmed: 23010076
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
J Immunother Cancer. 2019 Nov 14;7(1):302
pubmed: 31727154
Clin Cancer Res. 2018 Mar 1;24(5):1019-1029
pubmed: 28947565
Mayo Clin Proc. 2006 Feb;81(2):159-66
pubmed: 16471068
Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34
pubmed: 11900988
Cancer Res. 2012 May 15;72(10):2457-67
pubmed: 22589270
Semin Immunopathol. 2019 Jan;41(1):5-19
pubmed: 30203226
Oncoimmunology. 2017 Dec 26;7(3):e1404215
pubmed: 29399404
Mediators Inflamm. 2016;2016:5860657
pubmed: 27672242
Cancers (Basel). 2020 Oct 19;12(10):
pubmed: 33086698
Lancet. 1995 Nov 25;346(8987):1399-400
pubmed: 7475823
Leuk Lymphoma. 2017 Aug;58(8):1914-1921
pubmed: 27911124
Front Immunol. 2020 Nov 09;11:595035
pubmed: 33240282
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Leukemia. 2014 Jul;28(7):1552-5
pubmed: 24504025
J Transl Med. 2014 Feb 24;12:55
pubmed: 24565030
Nat Rev Cancer. 2014 Feb;14(2):135-46
pubmed: 24457417
Oncoimmunology. 2018 Jul 23;7(9):e1468957
pubmed: 30228936
Blood. 2016 Mar 10;127(10):1325-35
pubmed: 26668133
N Engl J Med. 2017 Jun 1;376(22):2168-2181
pubmed: 28564565
Oncoimmunology. 2017 Jul 5;6(10):e1345402
pubmed: 29123956
Clin Cancer Res. 2014 Jan 1;20(1):221-32
pubmed: 24218513
J Biol Chem. 2018 Jun 22;293(25):9555-9569
pubmed: 29769311
Leuk Res. 2016 Apr;43:39-43
pubmed: 26943702
J Immunol. 2015 Jan 1;194(1):21-7
pubmed: 25527793
Annu Rev Immunol. 2004;22:745-63
pubmed: 15032595
Semin Immunopathol. 2017 Apr;39(3):317-326
pubmed: 27677755
Blood Adv. 2018 Feb 13;2(3):224-234
pubmed: 29386195
Eur J Haematol. 2015 Mar;94(3):227-34
pubmed: 25082025
Cancer Discov. 2019 Sep;9(9):1192-1207
pubmed: 31266769
J Clin Oncol. 2011 Feb 20;29(6):761-70
pubmed: 21205761
Cancers (Basel). 2020 Jul 02;12(7):
pubmed: 32630667
J Clin Oncol. 2013 Jan 20;31(3):e44-7
pubmed: 23248243
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187